Loco‐regional radiotherapy in de novo metastatic nasopharyngeal carcinoma with chemotherapy and immunotherapy: A real‐world retrospective study from two cancer centers

Documenti analoghi

• Evaluating the reduction of elective radiotherapy fields for de novo metastatic nasopharyngeal carcinoma in the immunotherapy era
  di: Ting Jin, et al.
  Pubblicazione: (2024)
• Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma
  di: Zikun Yu, et al.
  Pubblicazione: (2024)
• Clinical characteristics and prognostic factors in nasopharyngeal carcinoma with brain metastasis: A retrospective, single‐center study
  di: Nan Huang, et al.
  Pubblicazione: (2024)
• The prevalence of gastroesophageal reflux disease and laryngopharyngeal reflux in patients with dysphagia after radiotherapy for nasopharyngeal carcinoma
  di: Peter K. M. Ku, et al.
  Pubblicazione: (2024)
• Effects of tislelizumab on health‐related quality of life in patients with recurrent or metastatic nasopharyngeal cancer
  di: Yunpeng Yang, et al.
  Pubblicazione: (2024)